REFERENCES

1. Warburg O. On the origin of cancer cell. Science 1956;123:309-14.

2. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.

3. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003;23:1149-54.

4. Eigenbrodt E, Gerbracht U, Mazurek S, Presek P, Friis R. Carbohydrate metabolism and neoplasia: new perspectives for diagnosis and therapy. In: Prestlow TG, Prestlow TP, editors. Biochemical and molecular aspects of selected cancers. Academic Press Inc.; 1994. pp. 311-85.

5. Israël M, Schwartz L. The metabolic advantage of tumor cells. Molecular Cancer 2011;10:1-12.

6. Icard P, Lincet H. Global view of the biochemical pathways involved in the regulation of metabolism of cancer cells. Biochimica et Biophysica Acta 2012;1826:423-33.

7. Newberne PM, Newberne JW. Lipotropes and cancer. Biomedical Research 2012;23:225-9.

8. Siddiqui RA, Harvey KA, Walker C, Altenburg J, Xu Z, et al. Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer 2013;13:418-34.

9. Israël M. A possible primary cause of cancer: deficient cellular interactions in endocrine pancreas. Molecular Cancer 2012;11:63-8.

10. Israël M. A primary cause of cancer: GABA deficiency in endocrine pancreas. Cancer Therapy 2012;8:171-83.

11. Israël M. Signaling and metabolism in cancer: endocrine pancreas deficiency and hybrid anabolism-catabolism, drugs that undo the process. Cancer Therapy 2014;10:1-12.

12. Israël M. Comment on cancer metabolism and on the role of the endocrine pancreas. J Clin Med Res 2014;6:490-1.

13. Israël M. Altered controls transforming normal metabolism into carcinogenic. J Cancer Prev Curr Res 2017;7:00228-33.

14. Solimena M, Folli F, Denis-Donni S, Comi GC, De Camilli P, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes. N Engl J Med 1988;318:1012-20.

15. Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, et al. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis. Diabetologia 2017;60:43-9.

16. Eto M. Regulation of cellular protein phosphatase 1 (PP1) by phosphorylation of the CPI-17 family, C-kinase- activated PP1 inhibitors. J Biol Chem 2009;284:35273-7.

17. Hohl CM. AMP deaminase in piglet cardiac myocytes: effect on nucleotide metabolism during ischemia. Am J Physiol 1999;276:H1502-10.

18. Node K, Kitakaze M, Minamino T, Tada M, Inoue M, et al. Activation of ecto-5‘-nucleotidase by protein kinase C, and its role in ischaemic tolerance in canine heart. Br J Pharmacol 1977;120:273-81.

19. Wan Y, Wang Q, Prud’homme GJ. Gabaergic system in the endocrine pancreas: a new target for diabetes treatment. Diabetes Metab Syndr Obes 2015;8:79-87.

20. Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, et al. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep 2010;23:1407-16.

21. Mayer N, Schweiger M, Romauch M, Grabner GF, Eichmann TO, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol 2013;9:785-7.

22. Ouyang J, Parakhia RA, Ochs RJ. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011;286:1-11.

23. Bucay AH. The biological significance of cancer: mitochondria as a cause of cancer and the inhibition of glycolysis with citrate as a cancer treatment. Medical Hypotheses 2007;69:826-8.

24. Schuller HM, Al-Wadei HA, Majidi M. GABA B receptor is a novel drug target for pancreatic cancer. Cancer 2008;112:767-78.